DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the company’s ongoing patent litigation. The Court upheld the March ruling by the U.S. District Court for […]
Author: Ken Dropiewski
JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials
Bottling and labeling partner Eurofins CDMO (Alphora Research, Inc.) to ensure JanOne clinical research maintains compliance with GMP and FDA regulations LAS VEGAS, Sept. 3, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability […]
Zynex Reports 83% Order Growth for July and August
ENGLEWOOD, Colo., Sept. 3, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced order growth for July and August 2020. Aggregate orders in July and August were 83% above the prior […]
Biofourmis Closes $100 Million Series C Funding Round Led by SoftBank Vision Fund 2 to Accelerate U.S. and Global Expansion
Funding to advance “home hospital” initiatives with health systems and “beyond the pill” digital therapeutics partnerships with pharmaceutical companies BOSTON, Sept. 3, 2020 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund […]
CryoLife Acquires Ascyrus Medical
ATLANTA, Sept. 2, 2020 /PRNewswire/ — CryoLife, Inc. (“CryoLife”;NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has acquired Ascyrus Medical LLC (Ascyrus). Ascyrus is a Florida-based, privately-held developer of the Ascyrus Medical Dissection Stent (AMDS™), the world’s first aortic arch remodeling device used for the […]
CMS Grants Additional Reimbursement For The Eluvia™ Drug-Eluting Vascular Stent System
MARLBOROUGH, Mass., Sept. 3, 2020 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System (IPPS). The NTAP designation, awarded to new medical […]
Sequana Medical announces H1 2020 results and provides business update
Published: Sep 03, 2020 POSEIDON – Implants in Canada continue; interim results expected H1 2021 RED DESERT – Implants continue; interim results expected Q4 2020 DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and Europe Continued growth in European commercial implants Secured additional funding extending cash runway into […]
Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold
– The LIFE-BTK trial will evaluate the company’s new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK) – Esprit BTK was granted breakthrough device designation by the U.S. FDA – There are no stents or drug-coated balloons currently approved for […]
Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States
IRVINE, Calif.–(BUSINESS WIRE)–Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc. (OTC: ELGXQ) (“Endologix” or the “Company”) today announced the first implant of its recently approved ALTO® endograft outside of the United States, completed by Andrew Holden, MD, and Andrew Hill, MD, of Auckland City Hospital, Auckland, New […]
BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ Transcatheter Ventricular Enhancement System. The […]



